UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 2,925 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) by 7.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 44,324 shares of the company’s stock after purchasing an additional 2,925 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in 4D Molecular Therapeutics were worth $247,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of FDMT. KLP Kapitalforvaltning AS acquired a new stake in 4D Molecular Therapeutics during the fourth quarter worth $48,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of 4D Molecular Therapeutics during the 4th quarter worth about $50,000. PNC Financial Services Group Inc. boosted its position in shares of 4D Molecular Therapeutics by 66.1% during the 4th quarter. PNC Financial Services Group Inc. now owns 9,124 shares of the company’s stock valued at $51,000 after acquiring an additional 3,630 shares in the last quarter. Daiwa Securities Group Inc. boosted its position in shares of 4D Molecular Therapeutics by 5,291.8% during the 4th quarter. Daiwa Securities Group Inc. now owns 9,921 shares of the company’s stock valued at $55,000 after acquiring an additional 9,737 shares in the last quarter. Finally, Velan Capital Investment Management LP bought a new stake in 4D Molecular Therapeutics in the fourth quarter valued at about $56,000. 99.27% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

FDMT has been the subject of several recent research reports. Weiss Ratings restated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Wednesday. Barclays dropped their target price on 4D Molecular Therapeutics from $45.00 to $38.00 and set an “overweight” rating for the company in a report on Friday, May 9th. Royal Bank of Canada decreased their price target on 4D Molecular Therapeutics from $39.00 to $35.00 and set an “outperform” rating on the stock in a research note on Monday, March 3rd. The Goldman Sachs Group lowered their price target on 4D Molecular Therapeutics from $51.00 to $44.00 and set a “buy” rating on the stock in a research report on Friday, May 9th. Finally, Chardan Capital dropped their price objective on 4D Molecular Therapeutics from $28.00 to $25.00 and set a “buy” rating for the company in a research note on Friday, May 9th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, 4D Molecular Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $29.56.

4D Molecular Therapeutics Price Performance

Shares of FDMT opened at $4.50 on Friday. The company has a market capitalization of $208.46 million, a P/E ratio of -1.58 and a beta of 2.84. 4D Molecular Therapeutics, Inc. has a one year low of $2.24 and a one year high of $28.93. The business’s 50 day simple moving average is $3.41 and its 200-day simple moving average is $4.56.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($0.02). On average, sell-side analysts anticipate that 4D Molecular Therapeutics, Inc. will post -2.84 EPS for the current fiscal year.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.